Heterogeneity and longevity of antibody memory to viruses and vaccines

Alice Antia, Hasan Ahmed, Andreas Handel, Nichole E. Carlson, Ian J. Amanna, Rustom Antia, Mark Slifka

    Research output: Contribution to journalArticle

    6 Citations (Scopus)

    Abstract

    Determining the duration of protective immunity requires quantifying the magnitude and rate of loss of antibodies to different virus and vaccine antigens. A key complication is heterogeneity in both the magnitude and decay rate of responses of different individuals to a given vaccine, as well as of a given individual to different vaccines. We analyzed longitudinal data on antibody titers in 45 individuals to characterize the extent of this heterogeneity and used models to determine how it affected the longevity of protective immunity to measles, rubella, vaccinia, tetanus, and diphtheria. Our analysis showed that the magnitude of responses in different individuals varied between 12- and 200-fold (95% coverage) depending on the antigen. Heterogeneity in the magnitude and decay rate contribute comparably to variation in the longevity of protective immunity between different individuals. We found that some individuals have, on average, slightly longer-lasting memory than others—on average, they have higher antibody levels with slower decay rates. We identified different patterns for the loss of protective levels of antibodies to different vaccine and virus antigens. Specifically, we found that for the first 25 to 50 years, virtually all individuals have protective antibody titers against diphtheria and tetanus, respectively, but about 10% of the population subsequently lose protective immunity per decade. In contrast, at the outset, not all individuals had protective titers against measles, rubella, and vaccinia. However, these antibody titers wane much more slowly, with a loss of protective immunity in only 1% to 3% of the population per decade. Our results highlight the importance of long-term longitudinal studies for estimating the duration of protective immunity and suggest both how vaccines might be improved and how boosting schedules might be reevaluated.

    Original languageEnglish (US)
    Article numbere2006601
    JournalPLoS Biology
    Volume16
    Issue number8
    DOIs
    StatePublished - Aug 10 2018

    Fingerprint

    Viruses
    Immunity
    Vaccines
    immunity
    vaccines
    Data storage equipment
    viruses
    antibodies
    Antibodies
    Vaccinia
    Diphtheria
    Rubella
    Vaccinium
    tetanus
    deterioration
    Tetanus
    Measles
    antigens
    Antigens
    duration

    ASJC Scopus subject areas

    • Neuroscience(all)
    • Biochemistry, Genetics and Molecular Biology(all)
    • Immunology and Microbiology(all)
    • Agricultural and Biological Sciences(all)

    Cite this

    Antia, A., Ahmed, H., Handel, A., Carlson, N. E., Amanna, I. J., Antia, R., & Slifka, M. (2018). Heterogeneity and longevity of antibody memory to viruses and vaccines. PLoS Biology, 16(8), [e2006601]. https://doi.org/10.1371/journal.pbio.2006601

    Heterogeneity and longevity of antibody memory to viruses and vaccines. / Antia, Alice; Ahmed, Hasan; Handel, Andreas; Carlson, Nichole E.; Amanna, Ian J.; Antia, Rustom; Slifka, Mark.

    In: PLoS Biology, Vol. 16, No. 8, e2006601, 10.08.2018.

    Research output: Contribution to journalArticle

    Antia, A, Ahmed, H, Handel, A, Carlson, NE, Amanna, IJ, Antia, R & Slifka, M 2018, 'Heterogeneity and longevity of antibody memory to viruses and vaccines', PLoS Biology, vol. 16, no. 8, e2006601. https://doi.org/10.1371/journal.pbio.2006601
    Antia A, Ahmed H, Handel A, Carlson NE, Amanna IJ, Antia R et al. Heterogeneity and longevity of antibody memory to viruses and vaccines. PLoS Biology. 2018 Aug 10;16(8). e2006601. https://doi.org/10.1371/journal.pbio.2006601
    Antia, Alice ; Ahmed, Hasan ; Handel, Andreas ; Carlson, Nichole E. ; Amanna, Ian J. ; Antia, Rustom ; Slifka, Mark. / Heterogeneity and longevity of antibody memory to viruses and vaccines. In: PLoS Biology. 2018 ; Vol. 16, No. 8.
    @article{0c62fc8407254fceb3addb2396fb2271,
    title = "Heterogeneity and longevity of antibody memory to viruses and vaccines",
    abstract = "Determining the duration of protective immunity requires quantifying the magnitude and rate of loss of antibodies to different virus and vaccine antigens. A key complication is heterogeneity in both the magnitude and decay rate of responses of different individuals to a given vaccine, as well as of a given individual to different vaccines. We analyzed longitudinal data on antibody titers in 45 individuals to characterize the extent of this heterogeneity and used models to determine how it affected the longevity of protective immunity to measles, rubella, vaccinia, tetanus, and diphtheria. Our analysis showed that the magnitude of responses in different individuals varied between 12- and 200-fold (95{\%} coverage) depending on the antigen. Heterogeneity in the magnitude and decay rate contribute comparably to variation in the longevity of protective immunity between different individuals. We found that some individuals have, on average, slightly longer-lasting memory than others—on average, they have higher antibody levels with slower decay rates. We identified different patterns for the loss of protective levels of antibodies to different vaccine and virus antigens. Specifically, we found that for the first 25 to 50 years, virtually all individuals have protective antibody titers against diphtheria and tetanus, respectively, but about 10{\%} of the population subsequently lose protective immunity per decade. In contrast, at the outset, not all individuals had protective titers against measles, rubella, and vaccinia. However, these antibody titers wane much more slowly, with a loss of protective immunity in only 1{\%} to 3{\%} of the population per decade. Our results highlight the importance of long-term longitudinal studies for estimating the duration of protective immunity and suggest both how vaccines might be improved and how boosting schedules might be reevaluated.",
    author = "Alice Antia and Hasan Ahmed and Andreas Handel and Carlson, {Nichole E.} and Amanna, {Ian J.} and Rustom Antia and Mark Slifka",
    year = "2018",
    month = "8",
    day = "10",
    doi = "10.1371/journal.pbio.2006601",
    language = "English (US)",
    volume = "16",
    journal = "PLoS Biology",
    issn = "1544-9173",
    publisher = "Public Library of Science",
    number = "8",

    }

    TY - JOUR

    T1 - Heterogeneity and longevity of antibody memory to viruses and vaccines

    AU - Antia, Alice

    AU - Ahmed, Hasan

    AU - Handel, Andreas

    AU - Carlson, Nichole E.

    AU - Amanna, Ian J.

    AU - Antia, Rustom

    AU - Slifka, Mark

    PY - 2018/8/10

    Y1 - 2018/8/10

    N2 - Determining the duration of protective immunity requires quantifying the magnitude and rate of loss of antibodies to different virus and vaccine antigens. A key complication is heterogeneity in both the magnitude and decay rate of responses of different individuals to a given vaccine, as well as of a given individual to different vaccines. We analyzed longitudinal data on antibody titers in 45 individuals to characterize the extent of this heterogeneity and used models to determine how it affected the longevity of protective immunity to measles, rubella, vaccinia, tetanus, and diphtheria. Our analysis showed that the magnitude of responses in different individuals varied between 12- and 200-fold (95% coverage) depending on the antigen. Heterogeneity in the magnitude and decay rate contribute comparably to variation in the longevity of protective immunity between different individuals. We found that some individuals have, on average, slightly longer-lasting memory than others—on average, they have higher antibody levels with slower decay rates. We identified different patterns for the loss of protective levels of antibodies to different vaccine and virus antigens. Specifically, we found that for the first 25 to 50 years, virtually all individuals have protective antibody titers against diphtheria and tetanus, respectively, but about 10% of the population subsequently lose protective immunity per decade. In contrast, at the outset, not all individuals had protective titers against measles, rubella, and vaccinia. However, these antibody titers wane much more slowly, with a loss of protective immunity in only 1% to 3% of the population per decade. Our results highlight the importance of long-term longitudinal studies for estimating the duration of protective immunity and suggest both how vaccines might be improved and how boosting schedules might be reevaluated.

    AB - Determining the duration of protective immunity requires quantifying the magnitude and rate of loss of antibodies to different virus and vaccine antigens. A key complication is heterogeneity in both the magnitude and decay rate of responses of different individuals to a given vaccine, as well as of a given individual to different vaccines. We analyzed longitudinal data on antibody titers in 45 individuals to characterize the extent of this heterogeneity and used models to determine how it affected the longevity of protective immunity to measles, rubella, vaccinia, tetanus, and diphtheria. Our analysis showed that the magnitude of responses in different individuals varied between 12- and 200-fold (95% coverage) depending on the antigen. Heterogeneity in the magnitude and decay rate contribute comparably to variation in the longevity of protective immunity between different individuals. We found that some individuals have, on average, slightly longer-lasting memory than others—on average, they have higher antibody levels with slower decay rates. We identified different patterns for the loss of protective levels of antibodies to different vaccine and virus antigens. Specifically, we found that for the first 25 to 50 years, virtually all individuals have protective antibody titers against diphtheria and tetanus, respectively, but about 10% of the population subsequently lose protective immunity per decade. In contrast, at the outset, not all individuals had protective titers against measles, rubella, and vaccinia. However, these antibody titers wane much more slowly, with a loss of protective immunity in only 1% to 3% of the population per decade. Our results highlight the importance of long-term longitudinal studies for estimating the duration of protective immunity and suggest both how vaccines might be improved and how boosting schedules might be reevaluated.

    UR - http://www.scopus.com/inward/record.url?scp=85053241230&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85053241230&partnerID=8YFLogxK

    U2 - 10.1371/journal.pbio.2006601

    DO - 10.1371/journal.pbio.2006601

    M3 - Article

    VL - 16

    JO - PLoS Biology

    JF - PLoS Biology

    SN - 1544-9173

    IS - 8

    M1 - e2006601

    ER -